Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Revenue of Enanta Pharmaceuticals, Inc. (ENTA)
Revenue in 2024 (TTM): $67.64 M
According to Enanta Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $67.64 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Enanta Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $67.64 M | $67.64 M | $-104,512,000 | $-117,788,000 | $-116,045,000 |
| 2023 | $79.2 M | $79.2 M | $-123,476,000 | $-130,995,000 | $-133,816,000 |
| 2022 | $86.16 M | $83.19 M | $-119,215,000 | $-122,188,000 | $-121,755,000 |
| 2021 | $97.07 M | $97.07 M | $-104,245,000 | $-107,579,000 | $-78,996,000 |
| 2020 | $122.47 M | $122.47 M | $-37,995,000 | $-35,019,000 | $-36,168,000 |
| 2019 | $205.2 M | $205.2 M | $40 M | $45.56 M | $46.38 M |
| 2018 | $206.63 M | $206.63 M | $90.85 M | $93.12 M | $71.96 M |
| 2017 | $102.81 M | $102.81 M | $26.75 M | $26.95 M | $17.71 M |
| 2016 | $88.27 M | $88.27 M | $32.5 M | $32.56 M | $21.67 M |
| 2015 | $160.88 M | $160.88 M | $124.79 M | $125.46 M | $78.99 M |
| 2014 | $47.74 M | $47.74 M | $19.34 M | $19.27 M | $34.44 M |
| 2013 | $32.05 M | $32.05 M | $9.25 M | $9.63 M | $9.63 M |
| 2012 | $41.71 M | $41.71 M | $21.57 M | $21.4 M | $21.4 M |
| 2011 | $41.88 M | $41.88 M | $26.97 M | $23.31 M | $23.31 M |
| 2010 | $22.76 M | $22.76 M | $8.3 M | $7.75 M | $7.9 M |